Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Leukemia and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-3RB/CD131/CSF2RB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSF2RB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CSF2RB Products |
| Gene Delivery | CSF2RB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry and functional signaling assays. |
View CSF2RB Products |
| Benchmark Ab | Anti-CSF2RB (Sequence of clinical benchmark) Recombinant positive control antibody for binding and blocking validation. |
View CSF2RB Products |
| Validator | CSF2RB siRNA Set For knockdown verification in target-specific validation assays. |
View CSF2RB Products |
| Related Target A | IL3RA (CD123) Alpha subunit of the IL-3 receptor. Co-expresses with CSF2RB to form the high-affinity IL-3 receptor complex. |
View IL3RA Products |
| Related Target B | IL5RA (CD125) Alpha subunit of the IL-5 receptor. Partners with CSF2RB in eosinophil-mediated inflammatory pathways. |
View IL5RA Products |
| Related Target C | CSF2RA (CD116) Alpha subunit of the GM-CSF receptor. Forms signaling complexes with CSF2RB to regulate myeloid cell activation. |
View CSF2RA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity by SDS-PAGE. |
| Heterodimerization and complex assembly verification | High-purity alpha subunit partner proteins (IL3RA, IL5RA, CSF2RA) available for co-binding SPR/BLI assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Sequence-verified siRNA included for specificity and knock-down verification. |
Live IL-3RB/CD131/CSF2RB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The common beta subunit (beta-c, encoded by CSF2RB) is a critical signaling node shared by the heterodimeric receptors for IL-3, IL-5, and GM-CSF. Because it orchestrates multiple pro-inflammatory and hematopoietic pathways, targeting CSF2RB offers a unique therapeutic angle compared to targeting individual alpha chains.
The race for CSF2RB therapeutics is intensifying, with major players shifting focus from traditional antagonist mAbs to multi-specific antibodies and cell therapies targeting hematological malignancies and severe autoimmune diseases. As first-generation blockading therapies reach the clinic, the next wave of R&D is targeting selective signaling inhibition and antibody-drug conjugates (ADCs) designed for selective ablation of myelogenous leukemia cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | CSL Behring, Janssen | Asthma, Rheumatoid Arthritis, PAP | Ligand-blocking assays (Requires high-purity CSF2RB ECD-Fc and alpha-subunit proteins) |
| Bispecific Antibody / CAR-T | Academic Institutes, Biotech Startups | Acute Myeloid Leukemia (AML) | Target density and specificity screening (Requires CSF2RB stable cell lines generated via Lentivirus) |
| Small Molecule Inhibitors | Incyte, Pfizer (JAK/STAT pathway focus) | Myeloproliferative Neoplasms | Downstream signaling validation (Requires sequence-verified siRNA knockdown controls) |